<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859531</url>
  </required_header>
  <id_info>
    <org_study_id>CF-GI-001</org_study_id>
    <nct_id>NCT03859531</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Study at Orkambi Therapy in CF Patients</brief_title>
  <official_title>Gastrointestinal Outcome Measures Before and After Orkambi Therapy in Cystic Fibrosis (CF) Patients Carrying the F508del Mutation on Both Alleles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivacaftor caused a significance increase in weight in patients carrying the G551D mutation
      and the etiology of this has largely remained unknown but may be due to improved function of
      the gastrointestinal tract. The combination therapy of Orkambi has been recently approved for
      subjects with Cystic Fibrosis homozygous for F508del mutation. This provides an opportunity
      to examine if there are any improvements in gastrointestinal function. The investigators aim
      to investigate various aspects of gastrointestinal and pancreatic function before and 6
      months after the commencement of Orkambi therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the entire intestinal mucosa via capsule endoscopy before and 6 months after
      Orkambi therapy to ascertain if the inflammatory changes in the intestine have improved. A
      marker of intestinal inflammation measured in the stool, Calprotectin, will be examined
      before and 6 months after Orkambi treatment. The investigators hypothesize that the result
      will be reduced on therapy.

      A marker of pancreatic exocrine function, pancreatic elastase, will be examined before and 6
      months after therapy to examine if the result has increased indicating improvement of
      exocrine pancreatic function

      Study Population All subjects with CF homozygous for the F508del mutation in Sweden eligible
      for Orkambi therapy, i.e. above 12 years of age, in total 145 patients in Sweden of which 60
      are taken care of at Stockholm CF Center; the investigators aim to examine 20 patients.

      Study Duration The duration will be 6 months for each patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of fecal calprotectin</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>Is a marker of intestinal inflammation measured in the stool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of fecal elastase-1</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>Is a test of pancreatic function measured in the stool.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in small bowel capsule endoscopy (SBCE)</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>The method of SBCE has been well established as a descriptive diagnostic tool for intestinal inflammation and has been used as an outcome measure in clinical trials. Erythema, petechiae, mucosal erosions and ulcerations will be assessed according to the Maiden criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>Inflammatory marker, unit mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sedimentation rate</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>Inflammatory marker, unit mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum electrophoresis.</measure>
    <time_frame>Change from baseline, 6 months after commencing treatment with Orkambi</time_frame>
    <description>Inflammatory markers: alpha-1-antitrypsin, haptoglobin, orosomucoid, immunoglobulin A, M and G.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver function tests</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>ALT, AST, ALP, gamma-GT. Unit: mikrokat/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bilirubin</measure>
    <time_frame>Change from baseline at 6 months after commencing treatment with Orkambi</time_frame>
    <description>Bilirubin. Unit: mikromol/L</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients planned to receive Orkambi</arm_group_label>
    <description>CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients, F508del homozygote, &gt;12 years of age, eligible and planned for Orkambi therapy
        in Clinical routine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF patients F508del homozygote

          -  &gt;12 years of age

          -  eligible for Orkambi therapy.

        Exclusion Criteria:

          -  Patients who the patency capsule does not pass within 48 hrs

          -  FEV1&lt;30%

          -  Pregnancy and breastfeeding women

          -  Liver function blood tests (AST, ALT, Gamma-GT, ALP) &gt;3 xULN

          -  Bilirubin &gt;2 xULN

          -  AST or ALT alone &gt;5 xULN

          -  Previous lung transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle de Monestrol, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stockholm CF Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stockholm CF Center</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle de Monestrol, MD PhD</last_name>
      <phone>+468 58580000</phone>
      <email>isabelle.demonestrol@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2016 Jan;61(1):198-207. doi: 10.1007/s10620-015-3834-2. Epub 2015 Aug 7.</citation>
    <PMID>26250833</PMID>
  </reference>
  <reference>
    <citation>Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.</citation>
    <PMID>26510034</PMID>
  </reference>
  <reference>
    <citation>Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8. doi: 10.1097/MPG.0b013e3181d1b013.</citation>
    <PMID>20512061</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Isabelle de Monestrol</investigator_full_name>
    <investigator_title>Director of Stockholm CF Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Because this would expose the patients too much</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03859531/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

